- |||||||||| Naphcon-A (naphazoline HCl) / Novartis, arbekacin (NPC-14) / Nobelpharma, Fucidin (fusidic acid) / LEO Pharma
Journal: Effects of thiram exposure on liver metabolism of chickens. (Pubmed Central) - Mar 17, 2023
Taken together, this research showed that thiram exposure significantly altered hepatic metabolism in chickens. Moreover, this study also provided a basis for regulating the use and disposal of thiram to ensure environmental quality and poultry health.
- |||||||||| Fucidin (fusidic acid) / LEO Pharma
Journal: Decreased efficacy of antimicrobial agents in a polymicrobial environment. (Pubmed Central) - Jun 24, 2022
This was subsequently confirmed through further genetic analyses. Our findings indicate that the polymicrobial nature of the CF airways is likely to have a significant impact on the clinical response to antimicrobial therapy.
- |||||||||| rifampicin / Generic mfg.
Journal: Comparative genome analysis of multidrug-resistant and susceptible Glaesserella parasuis strains isolated from diseased pigs in China. (Pubmed Central) - Sep 4, 2021
We also detected 30,599 single nucleotide polymorphisms (SNPs), including nonsynonymous SNPs in the aminoglycoside resistance gene aph(3'')-Ib, the fusidic acid resistance gene fusA, and the two rifampicin resistance genes rpoC and rpoB in HPS-1. These findings improve our understanding of the differences between MDR and susceptible isolates and will aid the development of treatment strategies to decrease the prevalence and disease burden caused by G. parasuis.
- |||||||||| Fucidin (fusidic acid) / Leo Pharma
Review, Journal: The Diverse Search for Synthetic, Semisynthetic and Natural Product Antibiotics From the 1940s and Up to 1960 Exemplified by a Small Pharmaceutical Player. (Pubmed Central) - Jul 1, 2020
The discovery process included contemporary approaches such as open innovation; targeting specific pathogens and/or specific organs in the patient; examining the effects of antimicrobial compounds on bacterial virulence as well as on antibiotic-resistant variants, and searching for antibiotic producers among microorganisms not previously well explored. These activities were promoted by the collaboration with a renowned Danish clinical microbiologist, K. A. Jensen, as well as company expertise in fermentation technologies, chemical synthesis and purification of bioactive compounds from organic materials.
- |||||||||| Garamycin (gentamicin sulfate) / Generic mfg.
Clinical, Journal: Emergence of Methicillin-Resistant Staphylococcus aureus Belonging to Clonal Complex 15 (CC15-MRSA) in Kuwait Hospitals. (Pubmed Central) - Mar 1, 2020
All 42 isolates were resistant to gentamicin, kanamycin, fusidic acid and cadmium acetate; 38 isolates were resistant to tetracycline...The isolates belonged to accessory gene regulator type II and capsular polysaccharide group 8 but lacked genes for Staphylococcus enterotoxins, toxic shock syndrome toxin, collagen-binding adhesins and Panton-Valentine leukocidin. This study revealed the emergence and transmission of a previously rare MRSA clone among human patients in Kuwait hospitals and highlights the increasing infiltration of rare MRSA into the human population.
- |||||||||| Fucicort (fusidic acid / betamethasone valerate) / LEO Pharma, Fucidin (fusidic acid) / LEO Pharma
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Efficacy and Safety of Fucicort (clinicaltrials.gov) - May 22, 2019
P3, N=68, Terminated,
This study revealed the emergence and transmission of a previously rare MRSA clone among human patients in Kuwait hospitals and highlights the increasing infiltration of rare MRSA into the human population. N=550 --> 68 | Trial completion date: Jan 2020 --> May 2019 | Recruiting --> Terminated | Trial primary completion date: Jan 2020 --> May 2019; Due to business strategic reasons, LEO Pharma has decided to close down the FCF-38 trial.
- |||||||||| Fucicort (fusidic acid / betamethasone valerate) / LEO Pharma, Fucidin (fusidic acid) / LEO Pharma
Trial completion date, Trial primary completion date: Efficacy and Safety of Fucicort (clinicaltrials.gov) - Nov 30, 2018
P3, N=550, Recruiting,
N=550 --> 68 | Trial completion date: Jan 2020 --> May 2019 | Recruiting --> Terminated | Trial primary completion date: Jan 2020 --> May 2019; Due to business strategic reasons, LEO Pharma has decided to close down the FCF-38 trial. Trial completion date: Apr 2019 --> Jan 2020 | Trial primary completion date: Apr 2019 --> Jan 2020
- |||||||||| Fucicort (fusidic acid / betamethasone valerate) / LEO Pharma, Fucidin (fusidic acid) / LEO Pharma
Enrollment open: Efficacy and Safety of Fucicort (clinicaltrials.gov) - Aug 13, 2018
P3, N=550, Recruiting,
Trial completion date: Apr 2019 --> Jan 2020 | Trial primary completion date: Apr 2019 --> Jan 2020 Not yet recruiting --> Recruiting
- |||||||||| Fucicort (fusidic acid / betamethasone valerate) / LEO Pharma, Fucidin (fusidic acid) / LEO Pharma
New P3 trial: Efficacy and Safety of Fucicort (clinicaltrials.gov) - Jan 10, 2018
P3, N=550, Not yet recruiting,
|
